Nicox’s eye drop candidate has cleared a second Phase 3 trial in conditions related to high blood pressure in the eyes, poising the company for an FDA filing in the first half of 2026. ...

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial

Following the licensing agreement for NCX470, Nicox’s stock rose by 60.6% in market trading.

Following the licensing agreement for NCX470, Nicox’s stock rose by 60.6% in market trading.

Plus, news about Clearside Biomedical: Nicox, Kowa ink licensing deal worth up to €191.5M: Kowa is gaining the exclusive rights to an experimental glaucoma treatment called NCX 470 in the US ...

(RTTNews) - Nicox SA announced the results of the Whistler Phase 3b exploratory clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering in healthy volunteers and ocular hypertensive patients. The company believes that the outcomes in favor of NCX 470 in several trabecular meshwork aqueous humour dynamics parameters are due to nitric oxide. The positive exploratory results suggest that further investigation may be warranted into the dual mechanism effect of NCX 470 on intraocular pressure. According to the company, the therapeutic characteristics of NCX 470 demonstrated in the Phase 3 program so far shows that the company has an approvable and differentiated asset with a promising clinical profile.

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream